Establishment of Four Subsidiaries in Indonesia
Referring to Financial Service Authority (“OJK”) Regulation No. 31/POJK.04/2015 on Information Disclosure of Material Facts by Issuer of Public Company and the Decision of the Board of Directors of the Indonesia No. Kep. 00015/BEI/01-2021 on the Amendment of Regulation No.
The Opening of Representation Office in South Korea
Referring to Financial Service Authority (OJK) Regulation No. 31/POJK.04/2015 on Information Disclosure of Material Facts by Issuer of Public Company and the Decision of the Board of Directors of the Indonesia No. 00015/BEI/01-2021 on the Amendment of Regulation No. I-E
Prospectus of Public Offering of Pyridam Farma Bond I 2020
Prospectus of Pyridam Farma Bond I 2020
Additional Information and/or Revision of the Abridged Prospectus of Public Offering of Pyridam Farma Bond I 2020
Additional Information Abridged Prospectus_04012021
Abridged Prospectus of Public Offering of Pyridam Farma Bond I 2020
Abridged Prospectus of Pyridam Farma Bond I (p.1) Abridged Prospectus of Pyridam Farma Bond I (p.2)
Change of The Company’s Logo of PT Pyridam Farma Tbk.
In commemoration of the 44th anniversary of PT Pyridam Farma Tbk. (the “Company”), the Company hereby announces the change of the Company’s logo to become as follows: The Company’s logo is changed pursuant with Decree of the Board of Directors of
Change of Corporate Secretary of PT Pyridam Farma Tbk.
Pursuant to Financial Service Authority Regulation No. 35/POJK.04/2014 regarding Corporate Secretary of Issuer or Public Company and based on Decree of the Board of Directors of PT Pyridam Farma Tbk. (the “Company”) No. 06/B/PYFA-I/XI/2020 dated 5 November 2020 regarding the Termination and Appointment
Report of the Mandatory Tender Offer Result
Report of the Mandatory Tender Offer Result
Non-binding Memorandum of Understanding in Relation to a Proposed Partnership for the Commercialization and Manufacture of Covid-19 Vaccine
The Board of Directors of PT Pyridam FarmaTbk (the “Company”) wishes to announce that the Company has on October 12, 2020 entered into a non-binding memorandum of understanding (“MOU”) with Vaxine Pty Ltd (“Vaxine”) to explore the commercialization and manufacture
Investment in the Subsidiary: Pyfa Health Singapore Pte. Ltd.
Letter to OJK No. 08_18 Sep 2020_Investment in the Subsidiary